Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.42
- Piotroski Score 3.00
- Grade Buy
- Symbol (AYTU)
- Company Aytu BioPharma, Inc.
- Price $2.35
- Changes Percentage (-0.64%)
- Change -$0.02
- Day Low $2.34
- Day High $2.43
- Year High $3.50
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.44
- Trailing P/E Ratio -1.24
- Forward P/E Ratio -1.24
- P/E Growth -1.24
- Net Income $-15,840,000
Income Statement
Quarterly
Annual
Latest News of AYTU
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Q4 2024 Aytu Biopharma Inc Earnings Call
Joshua Disbrow, CEO of Aytu Biopharma, discusses the fiscal 2024 Q4 earnings call with positive results. Focus on Rx business growth, pediatric portfolio improvement, and leveraging RxConnect for futu...
By Yahoo! Finance | 3 days ago -
Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long
Aytu BioPharma, Inc. is a pharmaceutical company approaching breakeven with potential for profitability in 2025. Analysts predict a 96% growth rate is needed for profitability, noting the company's hi...
By Yahoo! Finance | 3 weeks ago -
It's Unlikely That The CEO Of Aytu BioPharma, Inc. (NASDAQ:AYTU) Will See A Huge Pay Rise This Year
Aytu BioPharma's EPS increased by 71% in three years, but shareholders experienced a 97% loss. Shareholders can address concerns at the upcoming AGM on June 26, including CEO compensation....
By Yahoo! Finance | 3 months ago
